We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IGC Pharma Inc | AMEX:IGC | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0409 | -7.55% | 0.5011 | 0.633 | 0.49 | 0.628 | 1,705,718 | 00:37:20 |
India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that on March 2, 2021, the Company received one more patent (patent#10,933,082) from the United States Patent and Trademark Office (“USPTO”) for the Company’s cannabinoid composition and method for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma and other conditions. The patent application was filed on October 1, 2018. The latest patent approval adds to the Company’s existing patent portfolio, which includes patent issuances by the USPTO for seizure disorders and eating disorders.
About IGC:
IGC operates two lines of business: (i) infrastructure and (ii) life sciences. The Company is based in Potomac, Maryland, U.S.A. social media: www.igcinc.us, www.igcpharma.com, Twitter @IGCIR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005927/en/
Claudia Grimaldi info@igcinc.us Phone: 301-983-0998
1 Year IGC Pharma Chart |
1 Month IGC Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions